Restricted accessOtherFirst published online 2018-2
Reply to ‘Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Urinary Excretion of Intact and Total Angiotensinogen in Patients with Type 2 Diabetes’ by Yoshimoto Et Al.
YoshimotoT, FurukiT, KoboriH, . Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med2017;65:1057–61.doi:10.1136/jim-2017-000445
2.
SatirapojB, SiritaweesukN, SupasyndhO. Urinary angiotensinogen as a potential biomarker of diabetic nephropathy. Clin Kidney J2014;7:354–60.doi:10.1093/ckj/sfu059
3.
GremplerR, ThomasL, EckhardtM, . Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab2012;14:83–90.doi:10.1111/j.1463-1326.2011.01517.x
4.
ShaS, PolidoriD, FarrellK, . Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab2015;17:188–97.doi:10.1111/dom.12418
5.
CherneyDZ, PerkinsBA, SoleymanlouN, . Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients withtype 1 diabetes mellitus. Circulation2014;129:587–97.doi:10.1161/CIRCULATIONAHA.113.005081
6.
Lambers HeerspinkHJ, de ZeeuwD, WieL, . Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab2013;15:853–62.doi:10.1111/dom.12127
7.
CherneyDZ, PerkinsBA, SoleymanlouN, . Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int2014;86:1057–8.doi:10.1038/ki.2014.246
8.
HerasMM, RodríguezN, GonzálezJFN. The renin-angiotensin-aldosterone system in renal and cardiovascular disease and the effects of its pharmacological blockade. J Diabetes Metab2012;03:1–24.doi:10.4172/2155-6156.1000171
9.
KoboriH, NangakuM, NavarLG, . The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev2007;59:251–87.doi:10.1124/pr.59.3.3
